Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.82 |
| ▸ | GAA | P10253 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 7/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.36 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | RGS12 | O14924 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Am-461 SCHEMBL29567409 | 0.90 | CYP3A4 (1.00) | CYP3A4GAATSHRNFKB1TDP1 | |
| Am-461 SCHEMBL349848 | 0.90 | CYP3A4 (1.00) | CYP3A4GAATSHRNFKB1TDP1 | |
| Am-461 SCHEMBL14715972 | 0.89 | CYP3A4 (0.98) | CYP3A4GAATSHRNFKB1TDP1 | |
| Am-461 SCHEMBL14715969 | 0.89 | CYP3A4 (0.98) | CYP3A4GAATSHRNFKB1TDP1 | |
| SCHEMBL350178 | 0.89 | CYP3A4 (0.81) | CYP3A4ALDH1A1PTGDR2MAPTKDM4E | |
| SCHEMBL350295 | 0.83 | CYP3A4 (0.58) | CYP3A4GAATSHRNFKB1TDP1 | |
| SCHEMBL14733229 | 0.82 | CYP3A4 (0.85) | CYP3A4PTGDR2LMNAKDM4EPOLB | |
| SCHEMBL2361747 | 0.82 | CYP3A4 (0.85) | CYP3A4ALDH1A1PTGDR2LMNAKDM4E | |
| Am-461 SCHEMBL14715970 | 0.82 | CYP3A4 (0.84) | CYP3A4PTGDR2LMNAKDM4EPOLB | |
| SCHEMBL348018 | 0.81 | CYP3A4 (0.68) | CYP3A4PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071807-B2 | Antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2011-12-06 | — | — | US | claimed |
| JP-2011526930-A | — | — | 2011-10-20 | — | — | JP | claimed |
| US-20110190227-A1 | Antagonists of Prostaglandin D2 Receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | claimed |
| US-20110144160-A1 | Antagonists of Prostaglandin D2 Receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-06-16 | — | — | US | claimed |
| EP-2307362-A2 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | Amira Pharmaceuticals, Inc. (US) | 2011-04-13 | — | — | EP | claimed |
| US-20100004331-A1 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | US | claimed |
| WO-2010003120-A2 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | WO | claimed |
| US-9688624-B2 | DP2 antagonist and uses thereof | BRICKELL BIOTECH, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-9688624-B2 | DP2 antagonist and uses thereof | BRICKELL BIOTECH, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-9688624-B2 | DP2 antagonist and uses thereof | BRICKELL BIOTECH, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-20130053444-A1 | DP2 ANTAGONIST AND USES THEREOF | PANMIRA PHARMACEUTICALS, LLC (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130053444-A1 | DP2 ANTAGONIST AND USES THEREOF | PANMIRA PHARMACEUTICALS, LLC (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130053444-A1 | DP2 ANTAGONIST AND USES THEREOF | PANMIRA PHARMACEUTICALS, LLC (US) | 2013-02-28 | — | — | US | disclosed |
| WO-2011085033-A2 | DP2 ANTAGONIST AND USES THEREOF | AMIRA PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| US-20110144160-A1 | Antagonists of Prostaglandin D2 Receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| EP-2307362-A2 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | Amira Pharmaceuticals, Inc. (US) | 2011-04-13 | — | — | EP | disclosed |
| US-20100004331-A1 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| US-20100004331-A1 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| WO-2010003120-A2 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | WO | disclosed |
| WO-2010003127-A2 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004331-A1 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | CYP3A4 1441/4885GAA 3993/4885TSHR 426/4885 |
| US-20110144160-A1 | Antagonists of Prostaglandin D2 Receptors | PTGDR, PTGDR2, PTGER2 | CYP3A4 1441/4885GAA 3993/4885TSHR 426/4885 |
| US-20110190227-A1 | Antagonists of Prostaglandin D2 Receptors | PTGDR, PTGDR2, PTGER2 | CYP3A4 1367/4885GAA 3473/4885TSHR 555/4885 |
| US-20130053444-A1 | DP2 ANTAGONIST AND USES THEREOF | PTGER2, PTGDR2, PTGES2 | CYP3A4 2497/4885GAA 3084/4885TSHR 2624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.